Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Managing Obesity Medical Minute 2: Overcoming Clinical Inertia
  • CME
  • CE

Gain expert perspectives on current best practice for obesity treatment, including behavioral modifications and antiobesity agents.
Caroline M. Apovian, MD, FACP, FACN
Ken Fujioka, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Pharmacists: 0.25 contact hours (0.025 CEUs)
Released: March 25, 2020 Expiration: March 24, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Relate the safety, efficacy, and effect on comorbidities of antiobesity agents used as adjuncts to behavioral modifications
  • Describe how to address clinician and patient barriers to obesity treatment

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Caroline M. Apovian, MD, FACP, FACN

Professor of Medicine
Boston University School of Medicine
Director, Center for Nutrition and Weight Management
Boston Medical Center
Boston, Massachusetts

Caroline M. Apovian, MD, FACN, FACP, has disclosed that she has received consulting fees from EnteroMedics, Ferring, Gelesis, Merck, Novo Nordisk, Nutrisystem, Orexigen, Rhythm, Sanofi, Scientific Intake, SetPoint Health, Takeda, Xeno Biosciences, and Zafgen and funds for research support from Aspire Bariatrics, Gelesis, GI Dynamics, MetaProteomics, MYOS Corporation, Novo Nordisk, Orexigen, Pfizer, Takeda, and The Dr. Robert C. and Veronica Atkins Foundation.
Ken Fujioka, MD

Director of Nutrition and Metabolic Research
Diabetes and Endocrine
Scripps Clinic
La Jolla, California

Ken Fujioka, MD, has disclosed that he has received fees for non-CME/CE services from Novo Nordisk and consulting fees from Amgen, Boehringer Ingelheim, Gelesis, Janssen Global, Novo Nordisk, Phenomix, and Sunovion.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant financial relationships to disclose.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant financial relationships to disclose.
Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant financial relationships to disclose.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant financial relationships to disclose.
Julie Skowronski, FNP-BC
Julie Skowronski, MSN, has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for primary care clinicians (including MD, DO, NP and PA), nurses, pharmacists, and other healthcare providers who are part of the care team involved in the medical management of patients with obesity

Goal

The goal of this activity is to improve the competence of primary care physicians, nurse practitioners, physician assistants, and other members of the healthcare team in overcoming barriers to the treatment of patients with obesity.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Pharmacist Continuing Education

Credit Designation

CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-042-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 25, 2020, through March 24, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

From EULAR 2020, new data from RABBIT trial assessing risk of herpes zoster infection among RA patients by class of DMARD, as reported by CCO

Released: July 1, 2020

From EULAR 2020, new safety analysis of risk for thromboembolic events with tofacitinib and baricitinib in RA, reported by Clinical Care Options (CCO)

Released: July 1, 2020

New from EULAR 2020: risk of JAKi, IL-6i, abatacept vs TNFi discontinuation among patients with rheumatoid arthritis, as reported by Clinical Care Options (CCO)

Released: July 1, 2020

From CCO: companion migraine prophylaxis slideset with highlights from Do-It-Better RealCME on improving migraine treatment, and prevention

Wade Cooper, DO Released: June 25, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Novo Nordisk

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?